Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Leucovorin 38Fluorouracil 36Oxaliplatin 34Bevacizumab 34Irinotecan 32Cetuximab 23Capecitabine 18Panitumumab 14IFL protocol 7Folfox protocol 6Celecoxib 6Radiotherapy 5Nivolumab 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gene Expression Profiling 5regorafenib 4pembrolizumab 4dehydroftorafur 4Ramucirumab 4Fluorodeoxyglucose F18 4Floxuridine 4aflibercept 3Surgical Procedures, Operative 3Sorafenib 3Radiosurgery 3Ipilimumab 3Gemcitabine 3Fentanyl 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Colonic Neoplasms × Clobetasol × Clear all
NCT02368886 2025-06-18

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Academic and Community Cancer Research United

Phase 2 Completed
123 enrolled 21 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡